XML 23 R10.htm IDEA: XBRL DOCUMENT v3.25.1
CASH, CASH EQUIVALENTS, AND INVESTMENTS
 3 Months Ended
Mar. 31, 2025
Cash and Cash Equivalents [Abstract]  
CASH, CASH EQUIVALENTS, AND INVESTMENTS CASH, CASH EQUIVALENTS, AND INVESTMENTS
The amortized cost, gross unrealized gains and losses, and fair value of cash, cash equivalents, and marketable securities as of March 31, 2025 and December 31, 2024, were as follows (in millions):
March 31, 2025
Cost
Basis
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and Cash
Equivalents
Marketable
Securities
Cash$61 $— $— $61 $61 $— 
Money market funds498 — — 498 498 — 
Total$559 $— $— $559 $559 $— 
December 31, 2024
Cost
Basis
Unrealized
Gains
Unrealized
Losses
Fair Value
Cash and Cash
Equivalents
Marketable
Securities
Cash$60 $— $— $60 $60 $— 
Money market funds611 — — 611 611 — 
Equity securities8 — — 8 — 8 
Total$679 $— $— $679 $671 $8 
The Company had no marketable equity securities as of March 31, 2025. During the three months ended March 31, 2024, the Company recognized $2 million of net unrealized losses in the condensed consolidated statements of operations related to marketable equity securities held as of March 31, 2024.
A summary of non-marketable equity securities and equity method investment balances as of March 31, 2025 and December 31, 2024 were as follows (in millions):
March 31,
2025		December 31,
2024
Equity method investments$20 $20 
Non-marketable equity securities39 39 
Total$59 $59 
No unrealized losses were recognized during both the three months ended March 31, 2025 and March 31, 2024 in the condensed consolidated statements of operations related to non-marketable equity securities held as of March 31, 2025 and March 31, 2024, respectively.